ArticleFrontiers in medicine2026
Azelaic acid alleviates UVB-induced photoaging in keratinocytes by restoring Smad-dependent TGF-β signaling.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skin photoaging, primarily caused by chronic ultraviolet B (UVB) exposure, is characterized by cellular senescence and extracellular matrix (ECM) degradation. Suppression of transforming growth factor-β (TGF-β)/Smad signaling plays a critical role in UVB-induced collagen loss and impaired skin repair. Azelaic acid (AzA), a clinically established dermatological agent with antioxidant and anti-inflammatory properties, has been reported to maintain skin homeostasis; however, its mechanistic role in protecting against UVB-induced photoaging remains unclear. Objective: This study aimed to investigate whether AzA alleviates UVB-induced photoaging in keratinocytes and to determine whether its protective effects are mediated through the restoration of Smad-dependent TGF-β signaling. Methods: An in vitro UVB-induced photoaging model was established using HaCaT keratinocytes. Following UVB irradiation, cells were treated with AzA. Cell viability and cytotoxicity were evaluated using CCK-8 and LDH assays, respectively. Cellular senescence was assessed by senescence-associated β-galactosidase staining. ECM-related markers were measured by ELISA. TGF-β/Smad signaling activity was analyzed by Western blotting, quantitative real-time PCR, and immunofluorescence. The selective TGF-β/Smad inhibitor SB431542 was used to verify pathway dependence. A keratinocyte-fibroblast conditioned medium model was also employed to assess the paracrine regulation of fibroblast ECM metabolism. Results: AzA significantly attenuated UVB-induced cellular senescence and partially restored cell viability in HaCaT cells. It significantly increased pro-collagen I levels and reduced MMP-1 levels, indicating the restoration of ECM-related protein balance. Mechanistically, AzA reversed UVB-induced suppression of TGF-β/Smad signaling by enhancing Smad2/3 phosphorylation, decreasing Smad7 expression, promoting the nuclear translocation of phosphorylated Smad2/3, and restoring Smad-dependent transcription. Pharmacological inhibition of TGF-β/Smad signaling largely abrogated these protective effects. Conditioned medium from AzA-treated keratinocytes also improved ECM-related responses in fibroblasts in a Smad-dependent manner. Conclusion: AzA alleviates UVB-induced photoaging by restoring Smad-dependent TGF-β signaling, preserving ECM homeostasis, and modulating epidermal-dermal crosstalk in vitro. These findings provide mechanistic support for the potential application of AzA in anti-photoaging strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.